Findings

What do systematic reviews say?

27 questions · 29 findings · 4 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 17 · 58.6%GRADE not reported 0 · 0%Very low 4 · 13.8%Low 7 · 24.1%Moderate 0 · 0%High 1 · 3.4%

Clobazam vs placebo

50% or greater reduction in seizure frequency Number of seizures · patients with drug‐resistant epilepsy

1 finding from 1 review

Clobazam add‐on therapy for drug‐resistant epilepsy 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 47 participants
Very low

Clobazam vs placebo

Seizure freedom · patients with drug‐resistant epilepsy

1 finding from 1 review

Clobazam add‐on therapy for drug‐resistant epilepsy 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 175 participants
Very low

Clobazam vs placebo

Treatment withdrawal · patients with drug‐resistant epilepsy

1 finding from 1 review

Clobazam add‐on therapy for drug‐resistant epilepsy 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 197 participants
Very low

Clobazam vs placebo

Withdrawals due to adverse events · patients with drug‐resistant epilepsy

1 finding from 1 review

Clobazam add‐on therapy for drug‐resistant epilepsy 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 150 participants
Very low

Clobazam vs placebo

50% reduction in generalised‐onset seizure frequency Not measured · patients with drug‐resistant epilepsy

The review found no eligible studies for this question.

1 finding from 1 review

Clobazam add‐on therapy for drug‐resistant epilepsy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Clobazam vs placebo

50% reduction in focal‐onset seizure frequency Not measured · patients with drug‐resistant epilepsy

The review found no eligible studies for this question.

1 finding from 1 review

Clobazam add‐on therapy for drug‐resistant epilepsy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Clobazam vs carbamazepine

Time on allocated treatment (retention time) · people with focal or generalized seizures

The review found no eligible studies for this question.

1 finding from 1 review

Clobazam monotherapy for focal or generalized seizures 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Clobazam vs phenytoin

Seizure freedom · drug‐naïve people with focal or generalized seizures with solitary cysticercus granuloma

The review found no eligible studies for this question.

2 findings from 1 review

Clobazam monotherapy for focal or generalized seizures 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Clobazam monotherapy for focal or generalized seizures 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Clobazam vs phenytoin

50% responder rate · drug‐naïve people with focal or generalized seizures with solitary cysticercus granuloma

The review found no eligible studies for this question.

1 finding from 1 review

Clobazam monotherapy for focal or generalized seizures 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Clobazam vs phenytoin

Adverse effects requiring withdrawal/discontinuation of study medication · drug‐naïve people with focal or generalized seizures with solitary cysticercus granuloma

Clobazam showed no clear difference in adverse effects requiring withdrawal/discontinuation of study… compared with phenytoin (low certainty).

1 finding from 1 review

Clobazam monotherapy for focal or generalized seizures 2018 · Cochrane Headline outcomes only
RR 0.1 [0.01, 1.65]
1 study · 48 participants
Low

Clobazam vs carbamazepine

Retention [ · people with focal or generalized seizures

Clobazam showed no clear difference in retention at 12 months compared with carbamazepine (low certainty).

1 finding from 1 review

Clobazam monotherapy for focal or generalized seizures 2018 · Cochrane Headline outcomes only
RR 0.83 [0.61, 1.12]
1 study · 115 participants
Low

Clobazam vs carbamazepine

Seizure freedom · people with focal or generalized seizures

Clobazam showed no clear difference in seizure freedom at 4 weeks compared with carbamazepine (low certainty).

2 findings from 1 review

Clobazam monotherapy for focal or generalized seizures 2018 · Cochrane Headline outcomes only
RR 0.85 [0.55, 1.32]
1 study · 43 participants
Low
Clobazam monotherapy for focal or generalized seizures 2018 · Cochrane Headline outcomes only
RR 0.95 [0.66, 1.36]
1 study · 43 participants
Low

Clobazam vs carbamazepine

50% responder rate · people with focal or generalized seizures

Clobazam showed no clear difference in 50% responder rate compared with carbamazepine (low certainty).

1 finding from 1 review

Clobazam monotherapy for focal or generalized seizures 2018 · Cochrane Headline outcomes only
RR 1.18 [0.94, 1.48]
1 study · 43 participants
Low

Clobazam vs carbamazepine

Adverse effects requiring withdrawal/discontinuation of study medication · people with focal or generalized seizures

The review found no eligible studies for this question.

1 finding from 1 review

Clobazam monotherapy for focal or generalized seizures 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Clobazam vs phenytoin

Time on allocated treatment (retention time) · drug‐naïve people with focal or generalized seizures with solitary cysticercus granuloma

The review found no eligible studies for this question.

1 finding from 1 review

Clobazam monotherapy for focal or generalized seizures 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Clobazam vs phenytoin

Retention [ · drug‐naïve people with focal or generalized seizures with solitary cysticercus granuloma

Clobazam may leads to higher retention at 6 months (measured by the number of treatment failures… compared with phenytoin (low certainty).

1 finding from 1 review

Clobazam monotherapy for focal or generalized seizures 2018 · Cochrane Headline outcomes only
RR 1.43 [1.08, 1.9]
1 study · 48 participants
Low

Intermittent oral clobazam vs placebo

Recurrent seizure at 6 months · children with febrile seizures

Intermittent oral clobazam may leads to lower recurrent seizure at 6 months compared with placebo (low certainty).

1 finding from 1 review

Prophylactic drug management for febrile seizures in children 2021 · Cochrane Headline outcomes only
RR 0.36 [0.2, 0.64]
1 study · 60 participants
Low

Intermittent oral clobazam vs placebo

Recurrent seizure at 12 months · children with febrile seizures

The review found no eligible studies for this question.

1 finding from 1 review

Prophylactic drug management for febrile seizures in children 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intermittent oral clobazam vs placebo

Recurrent seizure at 18 months · children with febrile seizures

The review found no eligible studies for this question.

1 finding from 1 review

Prophylactic drug management for febrile seizures in children 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intermittent oral clobazam vs placebo

Recurrent seizure at 24 months · children with febrile seizures

The review found no eligible studies for this question.

1 finding from 1 review

Prophylactic drug management for febrile seizures in children 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found